{"id":"placebo-matching-dacarbazine","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL476","moleculeType":"Small molecule","molecularWeight":"182.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In a Phase 3 clinical trial, this placebo is formulated to match dacarbazine (an alkylating agent used in melanoma and other cancers) in appearance, administration route, and schedule, but contains no active drug. It serves as the control arm to assess the efficacy and safety of the actual dacarbazine treatment or another investigational agent being tested against it.","oneSentence":"This is a placebo control arm matching the active comparator dacarbazine, containing no active pharmaceutical ingredient.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:51.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial (specific indication unknown without trial protocol)"}]},"trialDetails":[{"nctId":"NCT05629702","phase":"PHASE2","title":"ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-02-03","conditions":"Glioblastoma, Brain Tumor, Cannabis","enrollment":120},{"nctId":"NCT03018288","phase":"PHASE2","title":"Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-21","conditions":"Glioblastoma","enrollment":90},{"nctId":"NCT05269355","phase":"PHASE2, PHASE3","title":"A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)","status":"TERMINATED","sponsor":"PTC Therapeutics","startDate":"2022-05-23","conditions":"Leiomyosarcoma","enrollment":359},{"nctId":"NCT01721772","phase":"PHASE3","title":"Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-18","conditions":"Melanoma","enrollment":418},{"nctId":"NCT01587144","phase":"PHASE2","title":"Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-06-19","conditions":"Glioblastoma Multiforme","enrollment":18},{"nctId":"NCT01860638","phase":"PHASE2","title":"A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-19","conditions":"Glioblastoma","enrollment":296}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching Dacarbazine","genericName":"Placebo matching Dacarbazine","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm matching the active comparator dacarbazine, containing no active pharmaceutical ingredient. Used for Control arm in Phase 3 trial (specific indication unknown without trial protocol).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}